<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746054</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-K-2017</org_study_id>
    <nct_id>NCT03746054</nct_id>
  </id_info>
  <brief_title>Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality</brief_title>
  <acronym>PALERMO</acronym>
  <official_title>Phase III Study, Randomized, Multicenter, Evaluating the Efficacy of a Cardiovascular Active Prevention Vs Usual Clinical Practice, on the Morbi-mortality Decrease in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the French National Cancer Institute, 35 000 new hematologic cancers are&#xD;
      observed in France representing 10% of the new cancers. Chronic Myeloid Leukemia (CML) is a&#xD;
      cancer involving the bone marrow and blood cells, the median age at diagnosis is 53 years in&#xD;
      the Western world. The prognosis is worse than many other cancers with net survival at 5&#xD;
      years of 26%.&#xD;
&#xD;
      Since the approval of imatinib, additional tyrosine kinase inhibitors (TKIs) have been&#xD;
      approved by the European Medicine Agency, including the second-generation TKIs nilotinib,&#xD;
      dasatinib, and bosutinib and the third-generation TKI ponatinib. Despite their effect on the&#xD;
      evolution of CML, there is increasing of cardiovascular toxicities which can impact patient&#xD;
      morbidity and mortality. The majority of the cardiovascular toxicities are associated with&#xD;
      the second- and third-generation TKIs. Nilotinib and ponatinib cardiovascular toxicity&#xD;
      including arterial and venous thromboembolism has decrease the benefit/risk ratio, 10% of&#xD;
      patients treated with nilotinib 300 mg twice daily and 15.9% treated with 400 mg twice daily&#xD;
      experienced a vascular complication including myocardial infarction /ischemic heart disease,&#xD;
      cerebrovascular accidents, or peripheral arterial disease. Regarding ponatinib, serious&#xD;
      arterial occlusive adverse reactions occurred in 19% of patients.&#xD;
&#xD;
      In an attempt to reduce major adverse cardiovascular events MACE due to nilotinib and&#xD;
      ponatinib, currently, then approach is driven by usual clinical practice without any robust&#xD;
      published evidence. The investigators aim to perform a national clinical trial, multicenter,&#xD;
      prospective, randomized, with two parallel comparative arms: experimental group with&#xD;
      cardiovascular active prevention vs non active cardiovascular active prevention based on&#xD;
      usual clinical practice. Our hypothesis is that active prevention of cardiovascular&#xD;
      toxicities with optimal medical treatment improves the benefit-risk ratio in CML patients.&#xD;
      The primary objective is Event Free Survival (EFS) at month 24.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At admission eligible patients are proposed to participate. Written consent is signed after&#xD;
      complete oral and written explanation of the protocol is signed.&#xD;
&#xD;
      The efficacity of the cardiovascular active prevention will be studied by comparing the rate&#xD;
      of Event free Survival between patients in the Experimental Arm Versus usual Clinical&#xD;
      practices&#xD;
&#xD;
      The duration of participation for a subject is equal to 2 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvementof the Event Free Survival (EFS) rate in CML patients with an active and systematic prevention for cardiovascular risk.</measure>
    <time_frame>24 months</time_frame>
    <description>The Event Free Survival (EFS) is based on the analysis of the time to an event occurrence.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>active prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>optimal medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual clinical practice</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>usual clinical practice in each center</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Optimal medical treatment</intervention_name>
    <description>Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months</description>
    <arm_group_label>active prevention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>usual clinical practice</intervention_name>
    <description>usual clinical practice in each center</description>
    <arm_group_label>usual clinical practice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over 18 years&#xD;
&#xD;
          -  CML &quot;Philadelphia chromosome&quot; in chronic phase treated with nilotinib or ponatinib&#xD;
             for, in first or second line&#xD;
&#xD;
          -  Written informed consent must be obtained prior to protocol-specific procedures&#xD;
&#xD;
          -  Affiliation to a social security category&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revascularization already decided and scheduled&#xD;
&#xD;
          -  Life threatening disease&#xD;
&#xD;
          -  Recent history of myocardial infarction or stroke&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Hypotension (Blood pressure &lt; 90/50mmHg)&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Women of childbearing potential not using appropriate contraceptive measures&#xD;
&#xD;
          -  Contraindication for statin&#xD;
&#xD;
          -  Contraindication for aspirin&#xD;
&#xD;
          -  Contraindication for ACEi or AT2 antagonists treatment&#xD;
&#xD;
          -  Known hypersensitivity to rosuvastatin or fluvastatin, other ingredients in the&#xD;
             product&#xD;
&#xD;
          -  Known hypersensitivity to aspirin, other ingredients in the product, other salicylates&#xD;
             or non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Known hypersensitivity to ACEi or AT2 antagonists treatment, other ingredients in the&#xD;
             product&#xD;
&#xD;
          -  Hereditary or idiopathic angioedema ; or history of angioedema&#xD;
&#xD;
          -  Hyperaldosteronism&#xD;
&#xD;
          -  Active liver disease, or unexplained, persistent elevations in serum transaminases&#xD;
&#xD;
          -  Severe renal impairment (creatinine clearance &lt;30 ml/min)&#xD;
&#xD;
          -  Myopathy&#xD;
&#xD;
          -  Concomitant cyclosporine treatment&#xD;
&#xD;
          -  History of gastrointestinal bleeding or perforation, related to previous NSAIDs&#xD;
             therapy&#xD;
&#xD;
          -  Severe heart failure&#xD;
&#xD;
          -  Concurrent severe diseases which exclude the administration of therapy&#xD;
&#xD;
          -  Patients under reinforced protection, deprived of liberty by judicial or&#xD;
             administrative decision, hospitalized without consent or admitted to a health or&#xD;
             social establishment for purposes other than research&#xD;
&#xD;
          -  Absence of affiliation to a social security agency&#xD;
&#xD;
          -  Inability to understand the instructions or objectives of the study&#xD;
&#xD;
          -  Absence of signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HENNI SAMIR, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Angers Teaching Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HENNI SAMIR, MD, PhD</last_name>
    <phone>33(0)241354617</phone>
    <email>samir.henni@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MARECHAL-GIRAULT STEPHANIE, MSc</last_name>
    <phone>33(0)241356208</phone>
    <email>StMarechal@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Henni</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood</keyword>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>Vascular medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

